CCHFW 16th Conference: NHM, food and drug reforms on agenda Monday
Synopsis
Key Takeaways
The Ministry of Health and Family Welfare (MoHFW) will convene the 16th Conference of the Central Council of Health and Family Welfare (CCHFW) in New Delhi on Monday, 30 June 2025, to deliberate on critical health policy priorities including the National Health Mission (NHM), food and drug reforms, and allied health services, according to an official ministry statement issued on Saturday, 27 June 2025. The high-level gathering brings together the Centre and all states and union territories under a single institutional platform for the first time this year.
Who Will Chair the Conference
Union Health and Family Welfare Minister J.P. Nadda will chair the conference, flanked by Ministers of State for Health and Family Welfare Anupriya Patel and Prataprao Jadhav. The ministerial presence underscores the Centre's intent to drive a coordinated national health agenda rather than leaving reform timelines to individual states.
Key Thematic Sessions
This year's conference will be structured around three thematic areas: the National Health Mission and its alignment with Sustainable Development Goal (SDG)-linked priorities; food and drug regulatory reforms; and the strengthening of allied health services. States and union territories will also be given a platform to present best practices and contribute to a coordinated national roadmap for improving health outcomes.
What the CCHFW Is and Why It Matters
Constituted under Article 263 of the Constitution, the CCHFW is the apex advisory body of the MoHFW. It reviews the implementation of policies and programmes related to medical and public health, and recommends measures for their effective rollout in partnership with states and union territories. The ministry described the conference as 'an important institutional mechanism for promoting cooperative federalism in the health sector.'
Proposed Drug Import Shelf-Life Reform
Separately, the MoHFW on Friday, 27 June 2025 proposed a significant easing of the residual shelf-life requirement for imported drugs. Under the proposed revision, the existing norm — which mandates that more than 60 per cent of a drug's shelf life must remain at the time of import — would be replaced with a flat minimum of 12 months remaining shelf life at the point of entry. If adopted, the change could widen the availability of specialised and rare imported medicines in India, particularly those with shorter overall shelf lives. The proposal is expected to be among the drug reform measures discussed at the conference.
What Comes Next
The conference is expected to produce a coordinated policy roadmap that state health departments will be asked to align with. Outcomes from the NHM review and drug reform discussions are likely to inform budgetary and regulatory decisions in the months ahead. Observers will watch for any firm timelines on the shelf-life norm revision and for clarity on how SDG health targets will be tracked at the state level.